Characteristics of infusion-related reactions to lecanemab in early Alzheimer's disease: A multicenter real-world study in Northwestern China - PubMed
3 hours ago
- #Alzheimer's disease
- #Infusion-related reactions
- #Lecanemab
- Infusion-related reactions (IRRs) are the most common adverse events linked to lecanemab in early Alzheimer's disease (AD).
- A real-world study in Northwestern China found a cumulative IRR incidence of 12.36%, with the highest occurrence at the first infusion (17.3%).
- Common symptoms of IRRs included fever (54.2%) and dizziness (16.7%), with 45.8% of reactions occurring 2-24 hours post-infusion.
- All IRRs were mild (Grade 1) and self-limited, showing no severe cases.
- Hypertension (OR = 5.017) and higher Fazekas score (OR = 2.734) were identified as independent risk factors for IRRs.
- The study highlights the role of cerebrovascular health in IRR susceptibility, with hypertension and white-matter hyperintensity severity as key risk factors.